Last Price$19.1(7.5%)
Market Cap$14.6B
LTM NOPAT
($213.7M)
NOPAT margin
N/A
5Y avg: 57,164.0%
EPV as % of EV
(21.9%)
Market-Implied Value of Growth,
MIVoG as % of EV
121.9%
Discount rate
7.8%
Stock quality
6/10
Good
SMMT Earnings Power Value Model
| (USD M) | Mar'20 | Jun'20 | Sep'20 | Dec'20 | Mar'21 | Jun'21 | Sep'21 | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTM Revenue % growth | 0.7 (98.6%) | 0.7 (63.6%) | 0.7 (42.5%) | 0.9 43.1% | 0.7 2.7% | 0.6 (15.2%) | 1.7 133.5% | 1.8 96.1% | 1.9 156.5% | 2.0 232.5% | 1.0 (45.2%) | 0.7 (61.0%) | 0.5 (75.6%) | 0.5 (77.7%) | 0.2 (75.3%) | 0.0 (100.0%) | 0.0 (100.0%) | (0.2) N/A | (0.2) N/A | 0.0 N/A |
LTM NOPAT % growth | (28.8) N/A | (37.7) 31.0% | (46.8) 24.1% | (52.3) 11.9% | (62.3) 19.0% | (71.5) 14.8% | (73.0) 2.0% | (88.5) 21.3% | (92.5) 4.5% | (81.4) (12.0%) | (82.7) 1.6% | (73.4) (11.2%) | 1,242.7 N/A | 1,238.3 (0.4%) | 1,281.7 3.5% | 1,220.2 (4.8%) | (100.5) N/A | (127.0) 26.4% | (186.8) 47.0% | (213.7) 14.4% |
Discount rate | 4.1% | 3.9% | 3.9% | 4.1% | 4.9% | 4.4% | 4.9% | 4.8% | 6.0% | 5.0% | 6.4% | 7.2% | 3.9% | 8.0% | 7.4% | 6.8% | 7.3% | 7.5% | 6.9% | 7.8% |
| Earnings Power Value (EPV) | (699.7) | (971.1) | (1,201.0) | (1,263.2) | (1,260.0) | (1,615.7) | (1,490.1) | (1,863.6) | (1,537.3) | (1,616.0) | (1,299.8) | (1,025.2) | 31,917.5 | 15,515.3 | 17,261.3 | 17,824.3 | (1,383.6) | (1,695.6) | (2,691.5) | (2,750.6) |
Enterprise Value (EV) | 91.4 | 134.9 | 199.5 | 348.6 | 397.8 | 627.7 | 369.5 | 168.2 | 183.6 | 46.4 | 140.9 | 779.5 | 786.6 | 1,613.4 | 1,197.0 | 1,739.0 | 2,825.2 | 5,426.8 | 14,571.0 | 12,545.5 |
| Market-Implied Value of Growth (MIVoG) | 791.1 | 1,106.1 | 1,400.5 | 1,611.8 | 1,657.8 | 2,243.4 | 1,859.6 | 2,031.9 | 1,720.8 | 1,662.4 | 1,440.6 | 1,804.7 | (31,130.9) | (13,901.9) | (16,064.3) | (16,085.3) | 4,208.8 | 7,122.4 | 17,262.6 | 15,296.1 |
| EPV as % of EV | (765.2%) | (719.6%) | (602.1%) | (362.4%) | (316.7%) | (257.4%) | (403.3%) | (1,107.8%) | (837.4%) | (3,481.8%) | (922.8%) | (131.5%) | 4,057.8% | 961.6% | 1,442.0% | 1,024.9% | (49.0%) | (31.2%) | (18.5%) | (21.9%) |
| MIVoG as % of EV | 865.2% | 819.6% | 702.1% | 462.4% | 416.7% | 357.4% | 503.3% | 1,207.8% | 937.4% | 3,581.8% | 1,022.8% | 231.5% | (3,957.8%) | (861.6%) | (1,342.0%) | (924.9%) | 149.0% | 131.2% | 118.5% | 121.9% |
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
SMMT NOPAT
Annual
Quarterly
LTM
SMMT Earnings Power Value and Enterprise Value
Annual
LTM
Enterprise Value Breakdown
EPV and MIVoG as % of EV
SMMT vs Peer Set: Earnings Power Value comparison
General
Earnings power value
Financial metrics
Company name
EPV as % of EV
MIVoG as % of EV
Revenue growth
EPS growth
Net income margin
Summit Therapeutics Inc.SMMT
(21.9%)
121.9%
N/A
(68.7%)
N/A
Median Peer Set
3.9%
96.1%
18.9%
(43.7%)
12.6%
Royalty Pharma plcRPRX
121.4%
(21.4%)
(3.8%)
(43.7%)
37.9%
United Therapeutics CorporationUTHR
107.6%
(7.6%)
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc.REGN
71.7%
28.3%
8.3%
10.4%
31.1%
Novo Nordisk A/SNVO
49.0%
51.0%
24.9%
142.8%
34.8%
Vertex Pharmaceuticals IncorporatedVRTX
7.1%
92.9%
11.7%
N/A
(4.9%)
Incyte CorporationINCY
0.7%
99.3%
14.8%
(94.0%)
0.8%
Alnylam Pharmaceuticals, Inc.ALNY
(6.0%)
106.0%
23.0%
(38.6%)
(12.4%)
argenx SEARGX
(12.2%)
112.2%
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
(66.1%)
166.1%
73.7%
(56.5%)
(35.9%)
BioNTech SEBNTX
(238.6%)
338.6%
(77.4%)
(89.7%)
24.4%
Explore more intrinsic value tools hub for SMMT
Reverse DCF
Intrinsic Value
Peter Lynch Fair Value
Discount rate
Earnings growth model
Relative Value
DCF value calculator
Ben Graham Fair Value
Peter Lynch charts
Margin of safety
FAQ
What is Summit Therapeutics Inc. Earnings Power Value?
As of Dec 31, 2024, Summit Therapeutics Inc.'s Earnings Power Value is approximately ($2,750.6M).
What is Summit Therapeutics Inc. EV (Enterprise Value)?
As of Dec 31, 2024, Summit Therapeutics Inc.'s Enterprise Value (EV) estimates at $12.5B.
What is Summit Therapeutics Inc. NOPAT?
As of Dec 31, 2024, Summit Therapeutics Inc.'s Net operating profit after tax (NOPAT) is approximately ($213.7M).